An Open-Label, Multi-Center Study Evaluating the Effect on Viral Activity and the Safety and Tolerability of Extended Treatment of Pegasys (Peginterferon Alfa 2a ) in Combination With Copegus (Ribavirin) in Genotype 1, 2 and 3 Chronic Hepatitis C Patients Defined as Slow Responders/Non-RVR.
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 09 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2013 Planned end date changed from 1 Nov 2014 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 03 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.